KYTX Smart Money
Kyverna Therapeutics, Inc.
1W: -6.8%
1M: -17.4%
3M: -20.4%
YTD: -35.8%
1Y: -24.3%
$5.63
+0.36 (+6.83%)
Weekly Expected Move ±7.5%
$5
$5
$5
$6
$6
Credit Risk of going bust: higher than 69% of companies Debt: 8.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.07 (down 99%), Kyverna Therapeutics, Inc. would be worth roughly what it owes.
Total debt $33.0M against a stock market value of $348.2M.
Distance to default 3.47 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $12.4M (short-term plus half of long-term), stock volatility 90.2%; Altman Z'' -3.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.07 (down 99%), Kyverna Therapeutics, Inc. would be worth roughly what it owes.
Total debt $33.0M against a stock market value of $348.2M.
Distance to default 3.47 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $12.4M (short-term plus half of long-term), stock volatility 90.2%; Altman Z'' -3.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q2 2026144
Institutions Holding
+19 vs prior
93.8%
Ownership
+11.36%
33
New
36
Increased
49
Reduced
21
Closed
👔 Insider Trades
23 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-05-27 | Aktar Mert | director | A-Grant/Award | 5,093 | $— | $0 | Filing |
| 2026-05-27 | Shaw Christi | officer: executive chairperson | F-Tax Withholding | 4,194 | $8.59 | $36K | Filing |
| 2026-05-27 | SEIDENBERG BETH C | director | A-Grant/Award | 5,093 | $— | $0 | Filing |
| 2026-05-27 | Cohen Fred E | director | A-Grant/Award | 5,093 | $— | $0 | Filing |
| 2026-05-27 | CLARK IAN T | director | A-Grant/Award | 5,093 | $— | $0 | Filing |
| 2026-02-24 | Emany Sravan Kumar | director | A-Grant/Award | 11,006 | $— | $0 | Filing |
| 2026-02-24 | Miller Andrew Craig | director | A-Grant/Award | 11,006 | $— | $0 | Filing |
| 2026-01-12 | Shaw Christi | officer: executive chairperson | A-Grant/Award | 30,000 | $— | $0 | Filing |
| 2026-01-12 | Shaw Christi | officer: executive chairperson | A-Grant/Award | 24,301 | $— | $0 | Filing |
| 2025-12-18 | Westlake BioPartners Opportunity Fund I, L.P. | 10% owner | P-Purchase | 133,333 | $7.50 | $1000K | Filing |
| 2025-12-18 | Westlake BioPartners Opportunity GP I, LLC | 10% owner | P-Purchase | 133,333 | $7.50 | $1000K | Filing |
| 2025-12-18 | Westlake BioPartners Fund I, L.P. | 10% owner | P-Purchase | 133,333 | $7.50 | $1000K | Filing |
| 2025-12-18 | Westlake BioPartners GP I, LLC | 10% owner | P-Purchase | 133,333 | $7.50 | $1000K | Filing |
| 2025-12-18 | SEIDENBERG BETH C | director | P-Purchase | 133,333 | $7.50 | $1000K | Filing |
| 2025-12-15 | Walker Karen Marie | officer: chief technology officer | S-Sale | 23,998 | $12.20 | $293K | Filing |
| 2025-05-29 | Aktar Mert | director | A-Grant/Award | 16,634 | $— | $0 | Filing |
| 2025-05-29 | CLARK IAN T | director | A-Grant/Award | 16,634 | $— | $0 | Filing |
| 2025-05-29 | Cohen Fred E | director | A-Grant/Award | 16,634 | $— | $0 | Filing |
| 2025-05-29 | SPIEGELMAN DANIEL K | director | A-Grant/Award | 16,634 | $— | $0 | Filing |
| 2025-05-29 | SEIDENBERG BETH C | director | A-Grant/Award | 16,634 | $— | $0 | Filing |
| 2025-05-29 | Shaw Christi | director | A-Grant/Award | 16,634 | $— | $0 | Filing |
| 2025-04-11 | Jones Ryan Alexander | officer: chief financial officer | A-Grant/Award | 12,000 | $— | $0 | Filing |
| 2025-04-11 | Walker Karen Marie | officer: chief technology officer | A-Grant/Award | 13,000 | $— | $0 | Filing |
🏛️ Congressional Trades
0 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| No congressional trades found | |||||
🏦 Top Institutional Holders
20 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| GordonMD Global Investments LP | 4,244,818 | $38M | — | 2026-06-30 | Filing |
| GILEAD SCIENCES, INC. | 4,126,119 | $37M | — | 2026-06-30 | Filing |
| BlackRock, Inc. | 3,134,807 | $28M | +2,257,729 | 2026-06-30 | Filing |
| Bain Capital Life Sciences Investors, LL | 2,885,000 | $26M | -225,000 | 2026-06-30 | Filing |
| AIGH Capital Management LLC | 2,795,797 | $25M | +795,797 | 2026-06-30 | Filing |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2,000,000 | $18M | — | 2026-06-30 | Filing |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,897,451 | $17M | +114,109 | 2026-06-30 | Filing |
| GEODE CAPITAL MANAGEMENT, LLC | 1,049,430 | $9M | +625,604 | 2026-06-30 | Filing |
| Insight Holdings Group, LLC | 989,054 | $9M | — | 2026-06-30 | Filing |
| MORGAN STANLEY | 982,307 | $9M | +5,018 | 2026-06-30 | Filing |
| STATE STREET CORP | 982,233 | $9M | +843,933 | 2026-06-30 | Filing |
| Propel Bio Management, LLC | 883,198 | $8M | +238,777 | 2026-06-30 | Filing |
| Woodline Partners LP | 845,325 | $8M | — | 2026-06-30 | Filing |
| MILLENNIUM MANAGEMENT LLC | 639,780 | $6M | -365,728 | 2026-06-30 | Filing |
| MBB PUBLIC MARKETS I LLC | 614,477 | $5M | — | 2026-06-30 | Filing |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 500,000 | $4M | — | 2026-06-30 | Filing |
| D. E. Shaw & Co., Inc. | 469,346 | $4M | -252,235 | 2026-06-30 | Filing |
| WELLS FARGO & COMPANY/MN | 373,009 | $3M | +258,610 | 2026-06-30 | Filing |
| UBS Group AG | 365,574 | $3M | -84,176 | 2026-06-30 | Filing |
| GOLDMAN SACHS GROUP INC | 335,230 | $3M | +122,320 | 2026-06-30 | Filing |